BHCM
HRTX icon

Brevan Howard Capital Management’s Heron Therapeutics HRTX Stock Holding History

Brevan Howard Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,036
Closed -$45.5K – 2280
2025
Q4 		$45.5K Buy
+35,036
New +$43.3K ﹤0.01% 1701
2025
Q3 		– Sell
-19,806
Closed -$41K – 2085
2025
Q2 		$41K Sell
19,806
-57,735
-74% -$118K ﹤0.01% 1811
2025
Q1 		$171K Buy
+77,541
New +$150K ﹤0.01% 1008

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Brevan Howard Capital Management's HRTX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 35,036 shares — an estimated $45.5K sold.

Brevan Howard Capital Management first reported a position in HRTX in Q1 2025 and held it in 3 quarters. The position peaked at $171K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 35,036 Heron Therapeutics shares in Q1 2026, an estimated $45.5K.
  • Brevan Howard Capital Management first reported a position in Heron Therapeutics in Q1 2025 and held it in 3 quarters.
  • Brevan Howard Capital Management's Heron Therapeutics position peaked at $171K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.